Insulet (PODD) EPS (Basic) Growth (3y) (2013 - 2026)
Insulet (PODD) EPS (Basic) Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.52 Bn | 175.22 Bn | 6.27 Bn | -6.52% |
| 2 | Stryker | 128.96 Bn | 126.09 Bn | 3.81 Bn | 7.60% |
| 3 | Medtronic | 107.99 Bn | 98.77 Bn | 6.41 Bn | 3.18% |
| 4 | Boston Scientific | 67.76 Bn | 66.31 Bn | 3.61 Bn | 62.89% |
| 5 | Edwards Lifesciences | 48.09 Bn | 44.41 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.30 Bn | 27.18 Bn | 750.30 Mn | 60.34% |
| 7 | GE HealthCare Technologies | 27.89 Bn | 25.61 Bn | 1.98 Bn | 29.37% |
| 8 | Smith & Nephew | 27.02 Bn | 26.45 Bn | - | - |
| 9 | Koninklijke Philips | 23.98 Bn | 20.86 Bn | 2.07 Bn | 30.65% |
| 10 | Insulet | 11.56 Bn | 11.07 Bn | 529.10 Mn | 56.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.13% |
| Dec 31, 2025 | 80.69% |
| Sep 30, 2025 | 165.04% |
| Jun 30, 2025 | 38.09% |
| Mar 31, 2025 | 7.96% |
| Dec 31, 2024 | 49.35% |
| Sep 30, 2024 | 82.12% |
| Jun 30, 2024 | 109.40% |
| Dec 31, 2023 | 96.71% |
| Sep 30, 2023 | 61.48% |
| Jun 30, 2023 | 20.50% |
| Mar 31, 2023 | 130.47% |
| Dec 31, 2022 | 43.74% |
| Sep 30, 2022 | -97.36% |
| Jun 30, 2022 | -186.72% |
| Mar 31, 2022 | 75.60% |
| Dec 31, 2021 | 36.87% |
| Sep 30, 2021 | 86.71% |
| Jun 30, 2021 | -135.38% |
| Dec 31, 2019 | 417.94% |